CpG-Enriched Parvovirus Genomic Engineering for Metastasis Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oncolytic parvoviruses, such as H-1PV, have limited anticancer efficacy and fail to effectively trigger an antitumor immune response, especially in conditions where they do not directly kill cancer cells, such as in metastases.
Innovation Solution
Engineering oncolytic parvoviruses with additional CpG motifs in their genome to enhance their ability to replicate in and kill cancer cells, while also acting as adjuvants to stimulate the immune system, specifically by increasing the number of immunostimulatory CpG motifs to improve vaccine efficacy and reduce metastatic rates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If wild type H-1PV is used as an adjuvant in vaccine, then it can be administered without direct oncolytic effects on metastases, but it fails to effectively trigger antitumour immune response and has limited anticancer efficacy
Solution Approach 1:
The patent modifies the viral genome by increasing the number of CpG motifs from the wild type configuration to an enriched configuration (e.g., JabCG2 variant with additional CpG motifs). This parameter change in the genomic structure enhances the immunostimulatory capacity of the virus, enabling it to effectively activate TLR9 and trigger robust antitumour immune responses while maintaining its safety profile as an adjuvant.
2Reliability
If CpG motifs are added to the H-1PV genome, then immunogenicity and immune stimulation are enhanced, but the genome complexity increases
Solution Approach 1:
The patent applies local quality modification by specifically targeting the CpG motif content within the viral genome rather than altering the entire genome structure. The CpG-enriched regions are localized insertions that enhance immunogenicity without requiring comprehensive genomic reconstruction, thus managing complexity while achieving the desired immune stimulation effect.
3Reliability
If parvovirus replicates selectively in neoplastic cells, then oncolytic activity is achieved, but the ability to amplify CpG motifs specifically at tumor site needs verification
Solution Approach 1:
The patent employs self-service mechanism where the parvovirus inherently replicates selectively in neoplastic cells due to its biological properties. This selective replication automatically leads to localized amplification of the CpG-enriched genome at the tumor site, eliminating the need for external control mechanisms and ensuring precise localization of immunostimulatory effects to the cancer tissue.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The CpG-enriched parvoviruses, like JabCG2, demonstrate enhanced immunogenicity, inducing markers of cellular immunity and dendritic cell activation, leading to a significant reduction in metastatic rates, even when they do not directly exert oncolytic effects on metastases, thereby improving overall anticancer therapy.
Implementation Method 1
the JabCG1 and JabCG2 genomes proved in vitro to be more potent triggers of TLR-9-mediated signalling than wild-type H-1PV DNA
Data Source
AI summary
A parvovirus characterized by a CpG-enriched genome, wherein the genome contains at least 2 additional CpG inserts that are not present in the wild type genome is described as well as the use of said parvovirus, e.g., a parvovirus based on parvovirus H1, LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus (RPV), Rat virus (RV), vectors based on the foregoing viral species, and/or cells capable of actively producing the foregoing viral species for the preparation of a pharmaceutical composition, e.g., for the treatment of cancer, preferably pancreas carcinoma, hepatoma or lymphoma.